HA155

CAS No. 1312201-00-5

HA155( CS-963 )

Catalog No. M26244 CAS No. 1312201-00-5

HA155 selectively and potently inhibits autotaxin with an IC50 of 5.7 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 67 In Stock
5MG 65 In Stock
10MG 103 In Stock
25MG 211 In Stock
50MG 332 In Stock
100MG 491 In Stock
200MG 702 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    HA155
  • Note
    Research use only, not for human use.
  • Brief Description
    HA155 selectively and potently inhibits autotaxin with an IC50 of 5.7 nM.
  • Description
    HA155 selectively and potently inhibits autotaxin with an IC50 of 5.7 nM.(In Vitro):HA155 completely attenuates the thrombin-mediated increase in platelet-derived LPA dose-dependently .HA155 is an ATX inhibitor by binding to the ATX active site .
  • In Vitro
    HA-155 inhibits ATX by binding to the ATX active site.HA155 completely attenuates the thrombin-mediated increase in platelet-derived LPA in a dose-dependent manner.
  • In Vivo
    ——
  • Synonyms
    CS-963
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    Antibacterial
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1312201-00-5
  • Formula Weight
    463.29
  • Molecular Formula
    C24H19BFNO5S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 10 mg/mL (21.58 mM)
  • SMILES
    O=C1N(CC2=CC=C(F)C=C2)C(S/C1=C\C3=CC=C(OCC4=CC=C(B(O)O)C=C4)C=C3)=O.[(Z)]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Guo B, et al. Clinical Pharmacokinetics of Levornidazole in Elderly Subjects and Dosing Regimen Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis. Clin Ther. 2017 Jul;39(7):1336-1346.
molnova catalog
related products
  • PDE IV-IN-1

    PDE IV-IN-1 is a potent phosphodiesterase 4 (PDE4) inhibitor with anti-inflammatory activity for the treatment of asthma, chronic obstructive pulmonary disease and other inflammatory diseases, and is a potential compound for the study of depression.

  • GSK-256066

    A potent, selective PDE4 inhibitor with pIC50 of 11.5, 11.3, 11.4, and 11.9 for PDE4B, A, C, and D, respectively.

  • SEP-0372814

    SEP-0372814 is a potent inhibitor of PDE10.